Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook

Coherus BioSciences reported Q1 2026 EPS of -0.25, in line with expectations, but revenue missed at $12.31 million versus $14.43 million expected, a 14.69% shortfall. LOQTORZI sales rose 61% year over year, though quarterly sales fell 4.8% sequentially amid severe winter weather, and the stock initially dropped 2.29% after hours. Management reiterated a 2026 path to $15 million per quarter and sees $30 million-$35 million quarterly sales in 2027, supported by pipeline readouts and tighter cost control.

Analysis

The print is less about a one-quarter miss than about how fragile CHRS’s recovery thesis still is: the market is paying for a clean commercial ramp, but the revenue base is still thin enough that a few weeks of interrupted dosing can distort the curve. That makes the stock highly sensitive to operational noise, while the company’s own commentary implies that recurring revenue is not yet “sticky” enough to fully smooth seasonal shocks. In other words, the equity is trading more like a launch-stage asset than a mature oncology royalty stream, which keeps downside convex if Q2 doesn’t re-accelerate.

The more interesting second-order effect is competitive positioning. Management is trying to reframe LOQTORZI as both a standalone product and a platform input for pipeline combinations, but that argument only matters if commercial execution funds the pipeline without repeated dilution. The cash raise buys time, not optionality; if mid-year tags read through poorly, the market will likely reprice the pipeline as development-stage science with limited balance-sheet support, which would compress the multiple faster than the headline revenue miss alone.

On the peer front, AMGN appears to be the clearest loser from the CCR8 commentary because a weak read-through on one program tends to contaminate the entire mechanism until later data differentiate target biology from molecule quality. ABBV and JNJ are better insulated: they benefit if the market concludes tagmokitug validates combination biology, but they don’t need CHRS to win. The contrarian setup is that CHRS may be underappreciated on timing — the next 6-8 weeks matter more than the quarter itself, because a clean Q2 rebound plus any signal in HCC or H&N could force a sharp short-covering move from sub-$2 levels.

Key Decisions for Investors

• Stay tactical short CHRS into the next 2-6 weeks if the stock re-rates on the ‘weather excuse’ alone; risk/reward favors fading strength unless Q2 weekly sell-through visibly re-accelerates.
• If holding a bearish view, express it with a put spread on CHRS into the August call rather than outright short stock; the main risk is a sharp squeeze on any mid-year pipeline headline.
• Watch AMGN as the cleaner public-market read-through on CCR8 skepticism; a relative underweight versus ABBV/JNJ makes sense until CHRS or peers show durable efficacy, not just mechanistic rhetoric.
• Consider a long JNJ / short AMGN pair for the next 1-3 months if you want to express selective confidence in combination oncology optionality while fading weaker CCR8 execution.
• Only get constructive on CHRS after two confirming data points: Q2 revenue inflecting back above the seasonal baseline and at least one mid-year clinical update showing signal/durability; absent both, the equity remains a financing-sensitive trade.